| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H33N4O6PS |
| Molecular Weight | 500.549 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)[C@H](C)NP(=O)(N[C@@H](C)C(=O)OCC)C1=CC=C(O1)C2=C(CC(C)C)SC(N)=N2
InChI
InChIKey=BYKBUQDQTLDNLE-KBPBESRZSA-N
InChI=1S/C21H33N4O6PS/c1-7-29-19(26)13(5)24-32(28,25-14(6)20(27)30-8-2)17-10-9-15(31-17)18-16(11-12(3)4)33-21(22)23-18/h9-10,12-14H,7-8,11H2,1-6H3,(H2,22,23)(H2,24,25,28)/t13-,14-/m0/s1
Managlinat dialanetil (MB06322 or CS-917) is an inhibitor of fructose 1,6-bisphphosphatase.
Managlinat dialanetil is a bisamidate prodrug and its activation requires a two-step enzyme catalyzed reaction. Metabasis Therapeutics Inc in collaboration with Daiichi Sankyo Co Ltd was developing managlinat dialanetil for the potential treatment of type 2 diabetes.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 16.0 nM [IC50] |
PubMed
ACTIVE MOIETY
SUBSTANCE RECORD
